1. Hologic upgraded to equal weight at Morgan Stanley

    MarketWatch – 1:52 PM ET 03/27/2020
  2. Show article details.

    Leap in CEO Pay Turns Into a Dive -- WSJ

    DJ Business News – 2:47 AM ET 03/24/2020

    Median raise last year was 11.1% but plunge in stocks knocks wind out of equity awards. This article is being republished as part of our daily reproduction of WSJ.com articles that also appeared in the U.S. print edition of The Wall Street Journal. Chief executives of large U.S. companies rode a more than decadelong bull market to a string of record pay days.

  3. Show article details.

    Coronavirus Caps Years of Rich Pay for Many CEOs

    DJ Business News – 7:04 AM ET 03/23/2020

    Chief executives of large U.S. companies rode a more than decadelong bull market to a string of record pay days. Now, the stock market's coronavirus-fueled swoon could wipe out hundreds of millions of dollars from executive pay packages and prompt a recalibration of how CEO compensation is set. The potential losses highlight the flip side of stock-based compensation, experts say.

  4. Show article details.

    CDC, public health labs have tested at least 54,205 Americans for coronavirus

    MarketWatch – 10:40 AM ET 03/21/2020

    At least 54,205 tests for COVID-19 have been conducted by public health organizations in the U.S., as of March 18, according to the Centers for Disease Control and Prevention. This includes 4,524 tests performed by the CDC and 49,681 tests by public health laboratories. At least four major diagnostics makers including Abbott Laboratories, Hologic Inc. (HOLX), Roche Holding AG (RHHBF) and Thermo Fisher Scientific Inc. (TMO) have made tests for the novel coronavirus.

  5. Show article details.

    CDC, public health labs performed at least 44,000 COVID-19 tests

    MarketWatch – 7:34 AM ET 03/20/2020

    At least 44,872 tests for COVID-19 have been conducted by public health organizations in the U.S., as of March 18, according to the Centers for Disease Control and Prevention. This includes 4,505 tests performed by the CDC and 40,367 tests by public health laboratories. At least four major diagnostics makers including Abbott Laboratories (ABT), Hologic Inc. (HOLX), Roche Holding AG (RHHBF) and Thermo Fisher Scientific Inc. (TMO) have said they are now making tests for the novel coronavirus.

  6. Show article details.

    Roche CEO says coronavirus test capacity too limited to screen all

    Reuters – 10:22 AM ET 03/19/2020

    Only high-risk patients and those showing signs and symptoms of the new coronavirus should be tested because capacity remains too limited to screen everybody, Roche Chief Executive Severin Schwan said on Thursday. "There is simply not enough capacity, and as we are all aware, the incidence rates are rapidly increasing," Schwan told reporters on a call with other drug industry executives.

  7. Show article details.

    CDC, public labs have conducted 37,824 COVID-19 tests

    MarketWatch – 7:41 AM ET 03/19/2020

    At least 37,824 tests for COVID-19 have been conducted in the U.S. by the Centers for Disease Control and Prevention and public health laboratories, as of March 17, according to the CDC. This includes a total of 4,484 tests conducted by the CDC and 33,340 tests conducted by public labs. The Trump administration has been criticized for the botched rollout of the tests and complaints about access to testing by those who are sick.

  8. Show article details.

    Abbott Labs gets FDA green light to ship coronavirus tests

    MarketWatch – 6:01 PM ET 03/18/2020

    Abbott Laboratories (ABT) said late Wednesday that it received an emergency authorization from the Food and Drug Administration to ship 150,000 tests for COVID-19, or infection from the SARS-CoV-2 coronavirus. The tests use Abbott's m2000 system, which is in use at more than 175 hospitals and labs in the U.S., and can run up to 470 tests in 24 hours, the company said. "Abbott is immediately distributing 150,000 tests and will continue ramping up production to the highest levels possible,...

  9. Show article details.

    CDC, public health labs have conducted at least 31,000 tests

    MarketWatch – 9:56 AM ET 03/18/2020

    At least 31,878 tests have been conducted for people suspected of having COVID-19, as of March 17, according to the most recent data provided by the Centers for Disease Control and Prevention. This includes specimens tested by public health laboratories and by the CDC. That's up from Tuesday's tally of 25,162 COVID-19 tests.

  10. Show article details.

    Hologic gets emergency use authorization for its COVID-19 test

    MarketWatch – 11:04 AM ET 03/17/2020

    Hologic Inc. (HOLX) said Monday it received emergency use authorization from the Food and Drug Administration for its COVID-19 test. The company, which said that labs with Hologic's (HOLX) molecular diagnostic platform can process up to 1,150 tests in one day, has previously entered into a funding agreement with the Biomedical Advanced Research and Development Authority to develop a test for the novel coronavirus. Hologic (HOLX) said it will provide labs with "tens of thousands" of tests in March;...

  11. Show article details.

    BRIEF-Hologic - U.S. FDA-Issuing Emergency Use Authorizations To Hologic For Its Panther Fusion Sars-Cov-2 Assay

    Reuters – 6:35 AM ET 03/17/2020

    Hologic Inc (HOLX): * U.S. FDA-ISSUING EMERGENCY USE AUTHORIZATIONS TO HOLOGIC FOR ITS PANTHER FUSION SARS-COV-2 ASSAY. * U.S. FDA-ISSUING EMERGENCY USE AUTHORIZATIONS TO LABORATORY CORPORATION OF AMERICA FOR ITS COVID-19 RT-PCR TEST Source text for Eikon: Further company coverage:

  12. Hologic stock price target cut to $50 from $60 at J.P. Morgan

    MarketWatch – 6:27 AM ET 03/17/2020
  13. Show article details.

    BRIEF-Hologic's Molecular Test For The Novel Coronavirus, Sars-Cov-2, Receives FDA Emergency Use Authorization

    Reuters – 9:34 PM ET 03/16/2020

    Hologic Inc (HOLX): * HOLOGIC’S MOLECULAR TEST FOR THE NOVEL CORONAVIRUS, SARS-COV-2, RECEIVES FDA EMERGENCY USE AUTHORIZATION. * NEW TEST WILL BE WIDELY AVAILABLE ON HOLOGIC'S FULLY AUTOMATED PANTHER FUSION SYSTEM, SIGNIFICANTLY ADDING TO TESTING CAPACITY Source text for Eikon: Further company coverage:

  14. Show article details.

    Hologic’s Molecular Test for the Novel Coronavirus, SARS-CoV-2, Receives FDA Emergency Use Authorization

    Business Wire – 7:54 PM ET 03/16/2020

    -- New Test Will be Widely Available on Hologic’s Fully Automated Panther Fusion® System, Significantly Adding to Testing Capacity -- -- Only High-Throughput System to Enable Simultaneous Testing for SARS-CoV-2 and Other Common Respiratory Viruses, Boosting Efficiency and Increasing Clinical Insight -- MARLBOROUGH, Mass. This press release features multimedia.

  15. Show article details.

    Hologic Places 1,000th Panther Molecular Diagnostics System in the United States

    Business Wire – 8:08 AM ET 03/12/2020

    Hologic (HOLX) announced today the 1,000th placement of a Panther system, the Company’s market-leading automated molecular instrument, in a United States diagnostics laboratory. This press release features multimedia.

  16. Show article details.

    Imaging Technology Helps Shape Diagnoses and Medical Response to Illnesses

    PR Newswire – 9:00 AM ET 03/10/2020

    NEW YORK, March 10, 2020 Among the many segments within the medical devices industry, one of the most vibrant is that of medical imaging technology.

  17. Show article details.

    BRIEF-HHS Supports Development Of First High-Throughput Covid-19 Diagnostic Test

    Reuters – 12:43 PM ET 03/09/2020

    Hologic Inc (HOLX): * HHS Supports Development Of First High-Throughput Covid-19 Diagnostic Test. * HHS - HOLOGIC'S MOLECULAR DIAGNOSTIC TEST BECOMES FIRST COVID-19 PRODUCT SELECTED FOR DEVELOPMENT THROUGH ASPR’S STREAMLINED SELECTION PROCESS. * HHS - BARDA TO CONTRIBUTE $699,000 TO ACCELERATE HOLOGIC’S DEVELOPMENT OF TEST THAT DETECTS GENETIC MATERIAL OF SARS-COV-2, VIRUS THAT CAUSES COVID-19.

  18. Show article details.

    Hologic gets U.S. funding for coronavirus test kit

    Reuters – 12:26 PM ET 03/09/2020

    The U.S. Department of Health and Human Services said on Monday it would contribute $699,000 to speed up Hologic Inc's (HOLX) development of a coronavirus diagnostic test.

  19. Show article details.

    German Lab Demonstrates Feasibility to Detect SARS-Coronavirus-2 (SARS-CoV-2) Using Hologic’s Panther Fusion® System

    Business Wire – 2:00 AM ET 03/05/2020

    – Laboratory Developed Test Uses Panther Open Access™ Functionality –. A molecular assay for detecting the novel coronavirus SARS-CoV-2 on the automated Panther Fusion® system has been developed by investigators at Hannover Medical School in Germany, Hologic (HOLX) announced today.

  20. Show article details.

    Hologic to Webcast Presentations at Upcoming Investor Conferences

    Business Wire – 5:02 PM ET 02/18/2020

    Hologic, Inc. (HOLX) announced today that the Company will present at these upcoming investor conferences: Each presentation will be webcast live and may be accessed through a link on the investors section of Hologic’s website at http://investors.hologic.com. The webcasts will be available for 30 days following the events.

Page:

Today's and Upcoming Events

  • Apr
    29

    HOLX to announce Q2 earnings (Unconfirmed)

Past Events (last 90 days)

  • Jan
    29

    HOLX announced Q1 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.